Background. Angiotensin II (Ang II) down-regulates renin expression in juxtaglomerular cells, however,
Introduction
Angiotensin II (Ang II) suppresses renin expression in the juxtaglomerular (JG) cells forming a negative feedback loop in the systemic RAS [1] . In vitro observations raised the possibility that, at least in experimental model systems, a positive feedback loop may be formed in the regulation of tissue RAS. In the rat hypothalamus, expression of renin mRNA was suppressed by enalapril [2] . In cardiac myocytes both mechanical stress and Ang II treatment directly increased renin expression in vitro [3] . Furthermore, proximal tubular renin expression was increased significantly in rats after subtotal nephrectomy and this increase was largely reduced by ACE inhibition [4] . These results, however, in most cases provide only an indirect indication and further evidence is needed to substantiate the hypothesis postulating a potential positive feedback loop. If the existence of such 'paradoxical' positive feedback was confirmed this might be one potential mechanism whereby Ang II would contribute to the pathogenesis of progressive tissue fibrosis.
Recent studies by Keen and Sigmund reported that in transgenic mice harbouring the human renin gene driven by a 900 bp long piece of the human renin promoter, Ang II in pressor dose induced an almost 2-fold increase of the human renin mRNA expression independent of the change in blood pressure. These results confine the 'paradoxical' upregulation of renin expression by Ang II to the proximal promoter of the renin gene. The authors also discussed whether the molecular details of this 'paradoxical' stimulatory effect of Ang II are unknown and need to be clarified [5] .
Regulation of the human renin promoter has been studied in several systems. These studies have identified numerous potential transcription factor binding sites within the proximal promoter [6, 7] . Konoshita et al. [7] have mapped six binding sites, including ones that are potential targets for mitogenactivated protein kinase (MAPK) cascades, within the first 500 bp of the promoter. Furthermore, Tamura et al. [8] have suggested that c-Jun may contribute to the activation of the mouse proximal renin promoter through a tentative binding site identified between À36 and À20 bp immediately 5 0 of the transcription start site of the mouse Ren-I C gene. Renal tubular cells express minimal or no renin under normal conditions; however, they are able to regulate the level of renin mRNA under low salt or high salt intake, or they can increase renin expression during chronic tubulointerstitial injury [9] . It has been suggested that regulation of renin expression in renal tubular cells is different from that in the JG cells [10] .
Ang II regulates gene transcription through several intracellular signal transduction pathways, including the protein kinase C (PKC) pathway as well as the different MAPK cascades: the extracellular signalregulated kinase (ERK1/2) [11] and the c-Jun N-terminal kinase (JNK) [12] . ERK1/2 is classically activated via the Ras-Raf-MEK pathway, but the molecular details of the activation of the JNK by G-protein coupled receptors are less well understood. Tyrosine kinases [13] , the small GTP-ase p21-Rac1 and the p21-activated kinase (PAK) [12] and recently the adaptor protein Nck have been suggested to be involved [12] .
In the present work we analysed signalling mechanisms employed by Ang II that may contribute to the 'paradoxical' up-regulation of the transcriptional activity of the human proximal renin promoter in an in vitro experimental model system in renal tubular cells. In transient transfection experiments using porcine proximal tubular cells stably expressing the rabbit AT 1 receptor (LLC-PK/AT 1 ) we have found that Ang II stimulated the transcriptional activity of several renin promoter-luciferase constructs. Inhibition of PKC and the ERK cascade did not block the stimulatory effect of Ang II. However, blocking tyrosine kinases or the JNK cascade abolished stimulation of the renin promoter. From these data we conclude that under experimental conditions Ang II may activate the renin transcription in renal tubular cells through a tyrosine kinase and JNK dependent pathway.
Materials and methods

Materials
Fetal bovine serum (FBS) and HEPES were purchased from Life Technologies GmbH (Karlsruhe, Germany), Dulbecco's modified eagle medium (DMEM), geneticin, Ang II, genistein, bisindolylmaleimide I and phorbol 12-myristate 13-acetate were from Sigma-Aldrich Co. (St Louis, MO, USA) and PD98059 was from Calbiochem (Darmstadt, Germany). Candesartan was a kind gift from Astra-Zeneca (Mo¨lndal, Sweden). The p-ERK (E-4) antibody was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) and phospho-SAPK/JNK (Thr183/Tyr 185) antibody was from New England Biolabs (Beverly, MA, USA). Anti-b-actin antibody was from Sigma-Aldrich Co.
Plasmids
The pGL 3 -582 reporter construct contained the À582 to þ16 fragment of the human renin promoter subcloned into the pGL 3 -basic luciferase reporter plasmid (Promega, Madison, WI, USA). Three other reporter plasmids, containing the 145 (À145 to þ16), 892 (À892 to þ16) and 2824 (À2824 to þ16) bp long piece of the promoter in the pGL 3 -basic plasmid, were also tested. These constructs were a kind gift from Dr F. Pinet (INSERM, Paris, France) [14] . The dominant negative (DN)-Ras, DN-Raf, DN-MEK and DNRac1 plasmids have been described previously in detail [11] . The JNK-binding domain (amino acids 127-281) of the murine JNK interacting protein-1 (JIP) was amplified by PCR with pfu from a murine brain cDNA library (Clontech, Palo Alto, CA, USA). The resulting PCR product, with a 5
0 Kozak sequence and a 3 0 stop codon added on to its ends, was inserted between the EcoRI and HindIII sites of the cytomegalovirus-driven expression vector, pcDNA 3 (Invitrogen, San Diego, CA, USA). The DN-JNK plasmid was a kind gift from Dr P. Andreka and Dr N. H. Bishopric (University of Miami, Miami, FL, USA) [15] . Plasmid sequences were verified by dideoxy-sequencing using Sequenase 2.0 (USB, Cleveland, OH, USA).
Cell culture and transfection
LLC-PK1 cells stably transfected with the rabbit AT 1 receptor (LLC-PK/AT 1 ; a kind gift from Dr R. C. Harris, Vanderbilt University, Nashville, TN, USA) were grown in DMEM supplemented with 10% FBS, 100 mg/ml streptomycin, 100 IU/ml penicillin and 600 mg/ml geneticin. For transfection the cells were plated onto 60 mm dishes. At 50% of confluence, transfection was performed using the calcium phosphate precipitation method with 2.5 mg reporter construct, 7.5 mg interfering plasmid or pcDNA 3 , the empty expression vector. The total amount of DNA was adjusted to 12.5 mg DNA/dish using pcDNA 3 . Sixteen hours later the cells were washed three times with phosphate-buffered saline (PBS) and were incubated further in serum-free DMEM. After 6 h the cells were treated with 10 À7 M Ang II or its vehiculum for 21 h. In some experiments pharmacological inhibitors or their solvents were applied for 45 min prior to administration of Ang II. Finally, the cells were washed three times with ice-cold PBS and scraped into 250 ml ice-cold 100 mM KH 2 PO 4 (pH 7.8) containing 1 mM DTT. Cell lysate was prepared by the freeze-thaw method and the cellular debris was removed by microcentrifuging at 14 000 r.p.m. (5 min, 4 C). Luciferase activity was assayed from the supernatant as described previously [11] .
Western blot analysis
After 4 h serum deprivation, cells were pretreated with specific inhibitors or DMSO and were then treated with 10 À7 M Ang II for an additional 15 min. Samples were then scraped into 250 ml Triton lysis buffer [30 mM HEPES (pH 7.4), 100 mM NaCl, 10 mM EDTA, 1 mM EGTA, 50 mM NaF, 1% Triton X-100, 1 mM PMSF, 20 mg/ml leupeptin, 20 mg/ml aprotinin, 5 mM benzamidine, 1 mM sodium orthovanadate) and were boiled in Laemmli sample buffer for 5 min. Equal amounts of protein ($10 mg) were then subjected to electrophoresis on an 8% SDS-polyacrylamide gel and transferred to nitrocellulose membrane (Bio-Rad). Blots were blocked in 5% non-fat milk or 5% albumin in TBS containing 0.1% Tween 20, then washed and incubated with the primary antibody, followed by extensive washing. Finally, blots were incubated with the appropriate horseradish peroxidaseconjugated secondary antibody and visualized by enhanced chemiluminescence (Amersham). Equal loading and transfer were confirmed by staining both the gel and the membrane with Coomassie blue and Ponceau stains, respectively. In addition, equal loading was demonstrated by stripping the membranes and reprobing with anti-b-actin antibody (Sigma). The blots shown are representative of at least three similar experiments and semi-quantitative analysis was performed using Scion Image 4.0.2 software. The results of the densitometry are shown as normalized ratios of the measured optical density of the p-JNK and b-actin blots.
Statistical analysis
All transfections were performed in duplicate and repeated at least four times. The result are shown as mean±SD and expressed as a ratio of the luciferase activity in the Ang IItreated groups compared to vehicle-treated groups (fold stimulation). Student's t-test or one-way ANOVA (where appropriate) was used to analyse the data.
Results
Ang II stimulates the transcriptional activity of the human renin promoter via the AT 1 receptor
As expected, Ang II stimulated the luciferase activity of the 582 bp long renin promoter-reporter construct (pGL 3 -582) in a dose-dependent manner in LLC-PK1/AT 1 cells. The strongest activation was measured at 10 À7 M Ang II (3.49±1.25, P<0.05). Candesartan, a specific AT 1 receptor blocker, completely abolished this effect (Figure 1 ). Similar stimulation was seen with three different renin promoter-luciferase constructs: specifically, fold stimulation of the transcriptional activity of the constructs containing 145, 892 and 2824 bp long pieces of the renin promoter were 2.18±0.3, 3.59±1.15 and 3.29±1.67, respectively. These results confirm the specificity of the observed effect and also suggest that the regulatory sequences required for the 'appropriate' inhibitory effect of Ang II lay further upstream in the gene. JNK but not the ERK cascade may be involved in the activation of the renin promoter
Ang II induces MAPK activation in different systems and both ERK and the JNK cascade were shown to contribute to the transcriptional effects of the peptide [11, 12] . Therefore, we set out to study the induction of MAPK phosphorylation, i.e. activation in tubular cells by Ang II. LLC-PK/AT 1 cells were stimulated with 10 À7 M Ang II and western blots using phospho-MAPK specific primary antibodies were performed. Ang II induced a 16.2±3.3-fold increase in ERK phosphorylation and a 3.84±1.1-fold increase in JNK phosphorylation indicating the activation of both kinases (Figure 2 ). The stimulation of both ERK and JNK activity by Ang II was abolished by preincubation of cells with candesartan (data not shown) suggesting clearly that MAPK activation by Ang II is an AT 1 -mediated effect in our tubular cells.
These findings raised the possibility that the MAPK cascades may play a role in the transcriptional activation of the renin promoter caused by Ang II. However, the MEK antagonist PD98059 at 6 Â 10 À5 M concentration, which inhibited ERK phosphorylation induced by Ang II, did not inhibit the effect of Ang II on the promoter (2.88±1.17 vs 2.4±0.68, NS; Figure 4 ).
To confirm that the ERK cascade plays no role in this process, expression vectors encoding dominantnegative mutants of members of the ERK cascade (DN-Ras, DN-Raf and DN-MEK) were co-transfected with the pGL 3 -582 luciferase construct. Fold stimulation in the presence of DN-Ras, DN-Raf and DN-MEK (3.31±0.83, 2.83±0.84 and 2.93±0.86-fold, respectively) was not different from fold stimulation in cells co-transfected with pcDNA3, the empty expression vector, confirming that the ERK cascade plays no role in the activation of the proximal renin promoter by Ang II.
Next we examined if the JNK cascade contributes to the transcriptional activation of the renin promoter by Ang II. Plasmids designed to block the JNK cascade, namely DN JNK or JIP, the JNK-binding domain of the murine JNK-interacting protein-1 were co-transfected with the pGL 3 -582 construct. JIP inhibits JNK, but not p38 kinase or ERK, by retaining JNK in the cytoplasm. Importantly, both DN JNK and JIP substantially inhibited the fold stimulation induced by Ang II (2.75±0.69 vs 1.6±0.23 and 1.8±0.34, respectively; P<0.01; Figure 3 ). Similar results were obtained by using the JNK inhibitor compound, SP600125 (data not shown). B.
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While in most systems p21Ras plays a role in ERK activation, another member of the p21GTP-ase family, p21Rac1, is thought to be involved in the activation of JNK [12, 13] . To further elucidate the elements of the signalling cascade leading to activation of the renin promoter in our system N17 Rac1, the DN mutant of p21-Rac1, was co-transfected. Interestingly, DN Rac1 had no influence on the effect of Ang II on the 582 bp renin promoter (2.75±0.69 vs 3.21±0.53, NS), suggesting that an alternative pathway may be responsible for JNK activation.
Inhibition of PKC did not block the activation of renin transcription
Ang II activates the PKC signalling pathway in several systems including tubular cells. To define the role of PKC in the stimulatory effect of Ang II, tubular cells transfected with the pGL 3 -582 promoter were preincubated with bisindolylmaleimide (Bis), a specific PKC inhibitor prior to Ang II stimulation. Bis (5 Â 10 À7 M) did not inhibit the stimulatory effect of Ang II on the human renin promoter. In fact, this intervention augmented the effect of Ang II by 30% (2.88±1.17 vs 3.82±2.14, NS; Figure 4 ). On the other hand, Bis, when used in the same concentration, prevented the stimulatory effect of phorbol 12-myristate 13-acetate (PMA) on the c-fos promoter in our tubular cells (data not shown), demonstrating that the inhibitor was able to block at least some PKC isoforms in our system. To further corroborate this finding, tubular cells were preincubated with 100 nM PMA for 24 h to deplete all isoforms of PKC. Similarly to Bis, depletion of the PKC isoforms did not inhibit the observed effect of Ang II on the pGL 3 -582 promoter (data not shown).
To completely exclude the contribution of PKC to the observed effect of Ang II on the renin promoter we have performed a series of experiments using PMA to stimulate PKC in tubular cells. Stimulation of the tubular cells transiently transfected with our renin promoter-luciferase reporter construct with 10 À7 M PMA caused no significant fold increase in the activity of the renin promoter (1.24 þ 0.45, P ¼ NS). These results together clearly exclude a role of PKC in mediating the stimulatory effect of Ang II on the proximal renin promoter.
Inhibition of tyrosine kinases partially blocks the stimulatory effect of Ang II
It has been demonstrated recently that transactivation of receptor tyrosine kinases or activation of cytoplasmic tyrosine kinases may play a role in transducing a signal from the AT 1 receptor into the cell [16] . Consequently, we examined the effect of tyrosine kinases on the transcriptional regulation of the renin promoter by Ang II. Preincubation of tubular cells with 10 À4 M genistein, a potent tyrosine kinase inhibitor, decreased the fold stimulation of Ang II by almost 50% (2.88±1.17 vs 1.57±0.45, P<0.01; Figure 4 ).
Tyrosine kinases may lay upstream of JNK
Several studies have recently reported that Ang II activates JNK via multiple tyrosine kinase pathways [12, 13] . In the last set of experiments we investigated if tyrosine kinases involved in the observed effect of Ang II were upstream of JNK activation. Genistein inhibited the Ang II-induced phosphorylation of JNK in western blot experiments (3.84±1.12 vs 1.31±0.56, P<0.01; Figure 5 ). Furthermore, preincubation with genistein of the tubular cells co-transfected with the JIP plasmid prior to Ang II treatment resulted in a 35% decrease of the fold stimulation of the pGL 3 -582 promoter (2.75±0.69 vs 1.75±0.48, P ¼ 0.006; Figure 3 ) that was not significantly different from the inhibitory effect of either genistein or JIP alone. These results altogether suggest that tyrosine kinases and JNK are arranged in a vertical, hierarchical signalling system where tyrosine kinases lay upstream of JNK activation.
Discussion
Recent results obtained in transgenic mice harbouring the human renin gene driven by a 900 bp long piece of the human renin promoter demonstrated that a pressor dose of Ang II caused a 2.1-fold increase in the human renin mRNA expression independent of the increase in blood pressure [5] . The results presented here, obtained in an in vitro transient transfection model employing a 582 bp long piece of the human renin promoter in proximal tubular cells, confirm and extend the above finding. We showed that in renal proximal tubular cells Ang II dose-dependently up-regulated the proximal renin promoter via the AT 1 receptor employing a tyrosine kinase and JNK dependent pathway. The 'paradox' response evoked by Ang II on the proximal renin promoter seen in both transgenic mice and in our in vitro system suggests that the regulatory elements responsible for the down-regulation of the renin gene are missing from the first 900 bp of the promoter, but are present in genomic constructs containing very large amounts of flanking DNA [5] . In fact, several upstream regulator elements have been identified in both the mouse and the human renin gene [17, 18] . It is therefore conceivable that some of these distant regulatory sequences, or a co-operation between distal and proximal regulatory sites mediate the physiologic inhibitory effect of Ang II in reninsecreting cells. In our in vitro model system, however, we showed for the first time that in addition to the protein-kinase A/cAMP system c-jun-N-terminalkinase (JNK) also stimulates the transcriptional activity of the proximal human renin promoter. Furthermore, we showed that in renal tubular cells JNK mediates the 'paradoxical' stimulatory effect of Ang II on the proximal renin promoter. Further studies in appropriate experimental settings need to be performed to test the hypothesis that the signalling mechanisms described in this work contribute to the 'paradoxical' up-regulation of the renin gene observed by others [2] [3] [4] [5] . If this hypothesis is proven, that will add substantially to our understanding of the role of the local RAS in the pathogenesis of progressive tissue fibrosis.
Recently, Muller et al. [19] reported that Ang II inhibited the renin promoter via PKC in the renin secreting As4.1 cells. They localized this effect within the first 2.9 kb of the promoter. Importantly, they showed that this inhibitory effect did not involve the AP1 binding sites localized to within the first 200 bp. On the other hand, we found that inhibition of PKC, either by using bisindolylmaleimide or by depleting the have not used shorter promoter constructs to further narrow down the localization of the potential transcription factor binding site responsible for the observed effect. Consequently, it is difficult to explain the apparent differences between their results and ours. However, cell type differences may provide a possible explanation. Numerous studies, including our earlier work, reported that Ang II regulates gene transcription at least in part through different MAP kinases [11] [12] [13] . Data presented here confirm that in proximal tubular cells Ang II activates both ERK and JNK. Inhibition of the Ras-Raf-ERK cascade by multiple approaches failed to inhibit the effect of ANG, demonstrating that ERK is not involved in the regulation of the human renin promoter by Ang II.
In contrast, inhibition of JNK either by overexpressing the JNK binding domain of the murine JNKinteracting protein (JIP) or a dominant inhibitory mutant of JNK1 prevented the effect of Ang II (Figure 4) , clearly pointing to the role of JNK in the observed effect. JNK phosphorylates specific subsets of transcription factors, such as c-jun, ATF-2 [13] and also members of the Ets-domain transcription factor family, such as Elk-1 [20] , resulting in transcriptional activation of target genes. Several potential transcription factor binding sites have been identified within the first 600 bp of the human renin promoter [7] , including an Ets-domain binding site. Furthermore, Tamura et al. [8] have demonstrated a tentative binding site identified between À36 and À20 bp immediately 5 0 of the transcription start site of the mouse Ren-I C gene. The presence of these potentially JNK responsive binding sites in the proximal renin promoter might explain downstream mechanisms linking JNK activation to enhanced promoter activity. These mechanisms, however, need further investigation.
The small p21 GTP-ase Rac1 was previously described as an upstream mediator of JNK [12, 13] . Moreover, tyrosine kinases were also shown to activate JNK via activating PAK through p21-Rac1 or directly [12] . We previously presented evidence that p21-Rac1 may participate in the intracellular signalling processes of Ang II [11] . However, overexpressing the dominant inhibitory mutant of p21-Rac1 did not inhibit the effect of Ang II on the renin promoter in proximal tubular cells, and this contradicted our hypothesis on the potential involvement of Rac1 in the observed effect.
Genistein, a non-selective tyrosine kinase inhibitor, prevented the Ang II-induced renin promoter activity, suggesting that tyrosine kinases are involved in this process. Transactivation of receptor tyrosine kinases (e.g. EGF receptor and PDGF receptor), through both Src-dependent and Src-independent mechanisms or activation of cytoplasmic tyrosine kinases may be responsible for this effect. Our preliminary results obtained in transient transfection experiments using an expression vector for the c-Src-N-terminal kinase (Csk) points to the potential involvement of the Src family of cytoplasmic tyrosine kinases in the observed effect of Ang II (data not shown). Further work to dissect the molecular mechanisms leading to increased JNK activity in our tubular cells upon Ang II stimulation and to identify the specific tyrosine kinases involved is under way in our laboratory. Finally, genistein abolished JNK phosphorylation and no further inhibition of the effect of Ang II was seen when JIP and genistein were used simultaneously. Based on these results we believe that the tyrosine kinases involved lay upstream of JNK in this system.
In summary, we have presented evidence for the first time that Ang II can stimulate transcriptional activity of the proximal human renin promoter in an in vitro model system through a tyrosine kinase and JNK dependent mechanism. Activation of JNK in this system is independent of p21-Rac1 and occurs through a tyrosine kinase pathway.
Based on the data presented here and also some indirect evidence reported in the literature we propose that paradoxical up-regulation of the renin expression by Ang II might occur in certain tissues under specific conditions and that this pathological feedback mechanism may contribute to an amplification of the activity of the local RAS and to the progression of tissue fibrosis. Further work, however, is needed to substantiate this hypothesis with direct experimental evidence.
